The preclinical data presented here strongly support the clinical testing of PI3K/mTOR pathway inhibitors, in particular p110α-selective PI3K inhibitors such as alpelisib, in patients with ER+/HER2−breast cancer experiencing disease progression on CDK4/6-based therapies. This evidence concerns the gene ESR1 and cancer.